Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection ModelMolnupiravir는 햄스터 감염 모델에서 신흥 SARS-COV-2 관심의 변형의 복제를 억제합니다.Clinical Trial Published on 2021-07-092022-08-13 Journal: The Journal of Infectious Diseases [Category] SARS, 변종, 비임상, 임상, 진단, 치료제, [키워드] affected antivirals arising B.1.1.7 B.1.351 B.1.351 variants breath clinical trials combating concern conserved coronavirus COVID-19 pandemic effective Efficacy exacerbated hamster hamsters Infection Model molnupiravir monoclonal antibodies monoclonal antibody Mutation Phase 2 phase 2 clinical trials Protein reduced SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants unlikely Vaccine variant variants VoC VOCs Wuhan strain [DOI] 10.1093/infdis/jiab361 PMC 바로가기 [Article Type] Clinical Trial
Evaluation of the efficacy and safety of recombinant erythropoietin on the improvement of hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial입원한 COVID-19 환자의 개선에 대한 재조합 에리트로포이에틴의 효능 및 안전성 평가: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-07-062022-09-10 Journal: Trials [Category] SARS, 임상, [키워드] 1:1 48 hours Adverse reaction Adverse reactions age approved Arm Bandar Abbas Blinding block randomization blood pressure Care checked chronic lung disease clinical clinical symptom clinical trial clinical trials Committee company comparator Patients composite endpoint control group Controlled clinical trial controls Coronary heart disease COVID-19 COVID-19 patient COVID-19 patients CRP Deep vein Deep vein thrombosis diabetes Diabetes Mellitus Diastolic blood pressure dissemination distilled water Efficacy and safety element End-stage renal disease endogenous enoxaparin erythropoietin ethics committee evaluate evaluate the effect excluded exclusion criteria expected Haemoglobin Health Health care heart disease hospitalised hospitalised COVID-19 patients Hypoxemia immune system infiltration injection intervals Intervention intervention group investigator Iran Laboratory test Laboratory tests LDH Liver disease Local Lung disease lung field lung infiltration lymphocyte Lymphocyte count lymphopenia Medical Science Medical Sciences medication minute number objective oral contraceptive outcome oxygen oxygen partial pressure oxygen saturation parallel-group partial pressure participant Patient PCR performed pharmaceutical Pharmaceutical Company Phase 2 Placebo positive Prevent principal investigator protocol randomised randomised controlled trial Randomized Randomly receive recombinant erythropoietin recruitment Registered registry renal disease reported respiratory respiratory rate Sample size saturation severe COVID-19 symptom severe COVID-19 symptoms Side effect Side effects Standard Standard of care status sterile water Study protocol subcutaneous injection subject supplementary material Systolic blood pressure tachypnea technology the ethics committee thrombosis title Treatment protocol treatment protocols Trial registration university vital signs water water for injection weakened immune system website [DOI] 10.1186/s13063-021-05363-w PMC 바로가기 [Article Type] Letter
Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial입원이 필요한 COVID-19 참전 용사 치료를 위한 호르몬 개입(HITCH): 최상의 지지 요법 대 최상의 지지 요법과 데가렐릭스의 다기관, 2상 무작위 대조 시험: 무작위 대조 시험을 위한 연구 프로토콜Study Protocol Published on 2021-07-052022-09-10 Journal: Trials [Category] SARS, 임상, [키워드] addition age Analysis androgen Androgen receptor Androgen suppression Anti-androgen anti-viral antibody approved association best Cell Chain Reaction Clinical improvement Clinical outcome clinical outcomes clinical trial Comorbidity coronavirus COVID-19 COVID-19 illness COVID-19 infection COVID-19 severity Cytokines degarelix determine double-blind Efficacy Exploratory analyses expression Factor FDA Hormone therapy Hospitalization Hospitalized host cell host cell surface Human hypertension IMPROVE include infection with SARS-CoV-2 Intervention Invasive mechanical ventilation investigated LHRH lung epithelium Luteinizing Hormone male mechanical ventilation Mortality multicenter Nasopharyngeal swab normal temperature outcome Patient patients hospitalized performed Phase 2 Placebo placebo-controlled polymerase chain polymerase chain reaction positive positive reverse transcriptase polymerase chain reaction primary endpoint Prostate cancer protease randomization Randomized Randomized controlled trial receptor signaling reduce required reverse transcriptase SARS-CoV-2 SARS-CoV-2 cell SARS-CoV-2 entry secondary endpoint severity severity of COVID-19 severity of illness single dose stratified Study protocol supportive care suppress symptom severity target tissue temperature therapeutic targeting therapy TMPRSS2 TMPRSS2 expression transcriptase Treatment Trial Trial registration veteran Viral Viral load with COVID-19 [DOI] 10.1186/s13063-021-05389-0 PMC 바로가기 [Article Type] Study Protocol
SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donorsSARS-CoV-2 항체 역학 COVID-19 발병 후 8개월: 회복기 혈장 공여자의 24%에서 스파이크 항체는 지속되지만 중화 항체 손실Clinical Trial Published on 2021-07-012022-09-11 Journal: European journal of internal medicine [Category] SARS, 임상, 진단, 치료기술, 치료법, [키워드] Analysis anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibodies antibody Antibody Response Antibody responses Antigen antigens Characteristics contraction convalescent plasma COVID-19 decrease Donor eight faster Follow-up Hospitalization human immune response Immunity intervals linear median monitoring Multivariate analysis multivariate regression analysis neutralization ability Neutralizing Neutralizing antibodies neutralizing antibody nucleocapsid Older age participated Patient persistence Phase 2 Phase 2 study random-effect regression analysis response Result SARS-CoV-2 SARS-CoV-2 antibody spike symptom onset symptoms onset tested Vaccination strategies Vaccine [DOI] 10.1016/j.ejim.2021.05.010 PMC 바로가기 [Article Type] Clinical Trial
High rate of HSV-1 reactivation in invasively ventilated COVID-19 patients: Immunological findings침습적으로 환기 된 COVID-19 환자에서의 높은 HSV-1 재 활성화율 : 면역 학적 소견Research Article Published on 2021-07-012022-09-10 Journal: PLoS ONE [Category] MERS, SARS, 치료기술, [키워드] activated acute respiratory distress acute respiratory distress syndrome analyzed Antiviral Beta CD38 CD8 T cell CD8 T cells Cohort Comprehensive Course COVID-19 COVID-19 patient decreased expression drop evaluated FACS analysis Factor Frequency functional Gene expression analysis HLADR HSV-1 IFI44L IFIT1 IL-1 Infection interferon interferon-stimulated genes invasive ventilation invasively ventilated patient invasively ventilated patients later phase lead MX1 occur patients PCR performed Peripheral blood Phase 1 Phase 2 predisposing factors pulmonary Quantitative Reactivation respiratory respiratory distress respiratory specimen respiratory specimens RSAD2 SARS-CoV-2 SARS-COV-2 infection screened secretion severe acute respiratory distress syndrome severe pneumonia shown significant increase significantly lower symptom onset syndrome T cells time Ventilated Whole blood [DOI] 10.1371/journal.pone.0254129 PMC 바로가기 [Article Type] Research Article
Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19결합 된 대사 활성화 제는 온화한 중등도의 CovID -19에서 회복을 가속화합니다Clinical Trial Published on 2021-06-282022-08-13 Journal: Advanced Science [Category] MERS, 임상, [키워드] accelerate activator adenine administration ambulatory patient ambulatory patients Amino acid antioxidant antioxidant metabolism changes Clinical data clinical trial CMAs Combined combined metabolic activator combined metabolic activators complete recovery comprehensive analysis conducted COVID‐19 COVID‐19 patients deficiencies deficiency double‐blinded phase effective glutathione glutathione metabolism immune response IMPROVE include Infection Inflammation inflammatory proteomics investigated l ‐carnitine l ‐carnitine tartrate lead lipid metabolism metabolic metabolic abnormalities metabolic function metabolism metabolite metabolites metabolomics mitochondrial mitochondrial dysfunction mixture NAD+ nicotinamide nicotinamide adenine dinucleotide nicotinamide riboside omics data Open‐label phase Patient patients treated Phase 2 phase 3 trial Phase 3 trials phase‐2 phase‐3 Placebo placebo group Placebo‐controlled Plasma level Plasma levels plasma metabolome plasma metabolomics precursor Protein proteome proteomics regulate respiratory respiratory problems reveal Safe salt shown significantly significantly shorter therapeutic regime therapeutic strategy Treatment [DOI] 10.1002/advs.202101222 PMC 바로가기 [Article Type] Clinical Trial
COVID-19 vaccine prioritization of incarcerated people relative to other vulnerable groups: An analysis of state plansResearch Article Published on 2021-06-152022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, [키워드] Analysis Care category conducted COVID-19 infection COVID-19 mitigation COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine dissemination distribution District document elevated eligible equity group Guidance incarcerated increased risk Infection initial morbidity phase Phase 1 Phase 2 protocol raise receive risk risk of COVID-19 state health department The United States the vaccine vaccination Vaccine website [DOI] 10.1371/journal.pone.0253208 PMC 바로가기 [Article Type] Research Article
Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and AuthorizationTozinameran (BNT162B2) 백신 : 전임상 연구에서 임상 시험 및 승인으로의 여정Review Published on 2021-06-072022-08-31 Journal: AAPS PharmSciTech [Category] MERS, SARS, 신약개발, 임상, 진단, [키워드] Administered administration adolescents adverse effects age antibody Antibody Response authorization bind BioNTech BNT162b1 BNT162b2 BNT162b2 vaccine BNT162b2 vaccines children clinical clinical trial clinical trials COVID-19 dosages Efficacy ENCODE EUA exhibited expected expression first dose host cells immune response Immunity individual Lipid nanoparticle Lipid nanoparticles mRNA Neutralizing antibodies of BNT162b2 Older operation participant Pfizer Pfizer-BioNTech Phase 1 phase 1 trials phase 1/2 trials Phase 2 phase 2 trials phase 2/ 3 trials phase 2/3 Phase 3 Phase 3 trials Preclinical preclinical studies preclinical trials pregnant pregnant women question real-world outcomes receive reported RNA robust S antigen Safety SARS-CoV-2 SARS-CoV-2 spike protein speed Spike protein Support the SARS-CoV-2 Tozinameran transfer Trial Vaccine [DOI] 10.1208/s12249-021-02058-y PMC 바로가기 [Article Type] Review
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial60세 이상의 건강한 성인을 대상으로 한 불활성화 SARS-CoV-2 백신(CoronaVac)의 안전성, 내약성 및 면역원성: 무작위, 이중 맹검, 위약 대조, 1/2상 임상 시험Randomized Controlled Trial Published on 2021-06-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] Adults Adverse reaction Adverse reactions age All participants Aluminium aluminium hydroxide antibody Antibody Response Antibody titre assigned baseline Beijing block Block randomisation China Chinese clinical trial CoronaVac COVID-19 COVID-19 vaccine Cutoff defined detectable development dose dose-escalation double-blind eight Endpoint enrolled groups healthy hydroxide immunogenicity inactivated injection injection site pain intervention group Intramuscular injection investigators Laboratory live SARS-CoV-2 Mild moderate morbidity morbidity and mortality Neutralising Antibodies neutralising antibody neutralising antibody titres occurred Older Older adults participant Participants Phase 1 Phase 2 phase 3 trial Placebo placebo group placebo-controlled positive primary immunogenicity Program random assignment randomised Randomly receive Registered reported research and development Safe Safety safety population SARS-CoV-2 SARS-CoV-2 vaccine Science second dose Serious Adverse Events Seroconversion seroconversion rate seronegative seropositive Seven severity technology the disease the placebo group titre Tolerability treatment allocation trial protocol vaccination Vaccine virus [DOI] 10.1016/S1473-3099(20)30987-7 PMC 바로가기 [Article Type] Randomized Controlled Trial
Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infectionClinical Trial Published on 2021-06-012022-10-05 Journal: Pathogens and global health [Category] 임상, [키워드] addition Admission age Antibiotics Anticoagulant approved Brazil caused Chloroquine coronavirus Corticosteroid COVID-19 death diabetes double-blind drug drugs Effectiveness Efficacy Endpoint form groups HCQ Hospital admission hospitalized patient Hydroxychloroquine ICU ICU admission incidence independent independent risk factor invasive ventilation IRB Ivermectin male manifestation Mortality no difference not reduce obesity objective Older pandemic participant Patient patients patients hospitalized performed Phase 2 Phase 2 study Physicians predictor pulmonary involvement Randomized randomized study reference Result safety profile SARS-COV-2 infection Serious Adverse Event supplemental oxygen tested three group [DOI] 10.1080/20477724.2021.1890887 PMC 바로가기 [Article Type] Clinical Trial